- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Samsung Bioepis' Trastuzumab Biosimilar, SB3, Approved in Republic of Korea
Samsung Bioepis announced this week that it has gained regulatory approval in the Republic of Korea for its trastuzumab biosimilar, SB3.
Samsung Bioepis announced this week that it has gained regulatory approval in the Republic of Korea for its trastuzumab biosimilar, SB3.
The Korea Herald reports that the biosimilar, referenced on Herceptin, was granted a marketing approval by the Korean Ministry of Food and Drug Safety for the treatment of metastatic breast cancer, early breast cancer, and metastatic gastric cancer. Samsung Bioepis plans to sell the drug under the brand name Samfenet. The next steps for the biosimilar developer are selecting a marketing partner for commercializing the drug and completing drug pricing procedures for the Korean marketplace.
The Republic of Korea has thus far approved 3 other biosimilars made by Incheon-based Samsung Bioepis: etanercept (referenced on Enbrel), infliximab (referenced on Remicade), and adalimumab (referenced on Humira). Samsung Bioepis has already launched its etanercept and infliximab products, but awaits Korean patent expiry of Humira—in January 2019—before it will begin to sell its adalimumab treatment.
SB3 also earned a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) in September 2017. If SB3 is granted a final marketing authorization by the European Commission, the company plans to sell the biosimilar in the European marketplace under the brand name Ontruzant. The drug will be marketed in Europe by MSD (known as Merck in the United States), and is poised to become the first biosimilar trastuzumab available in the European marketplace.
Meanwhile, the United States awaits a trastuzumab biosimilar of its own; while Samsung Bioepis has not announced a filing for SB3 with the FDA, the US regulatory body is currently reviewing a trastuzumab biosimilar, MYL-1401O, developed by Mylan and Biocon. Though the drug had a Biosimilar User Fee Act (BsUFA) target date of September 3, 2017, Biocon announced in late August that the FDA would not issue a regulatory decision on the product until December 3.
FTC Releases Second Report on PBMs Meddling in Generic Drug Markets
January 19th 2025The 3 largest pharmacy benefit managers (PBMs) increased many specialty generic drugs prices by hundreds of percent, with some drugs seeing thousands of percent markups, according to the Federal Trade Commission (FTC)’s second interim report on PBM practices.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Eye on Pharma: Korean Drugmakers’ Impact in Europe; New Denosumab, Eculizumab Deals
January 11th 2025Korean drugmakers hold over 50% market share in the 6 best-selling biosimilar markets, 2 companies sign exclusive licensing partnership for a denosumab biosimilar, and 2 others join forces for an eculizumab biosimilar.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Senators Introduce Bipartisan Legislation to Protect Skinny Labeling
January 2nd 2025To close out the year, 4 senators came together to introduce a new bipartisan bill to protect biosimilar and generic drug manufacturers from patent litigation when obtaining “skinny label” approvals for their products.
